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OBJECTIVE: To identify the prevalence and factors associated with cervical human papillomavirus infection in
women with systemic lupus erythematosus
METHODS: This cross-sectional study collected traditional and systemic lupus erythematosus-related disease risk
factors, including conventional and biologic therapies. A gynecological evaluation and cervical cytology screen
were performed. Human papillomavirus detection and genotyping were undertaken by PCR and linear array
assay.
RESULTS: A total of 148 patients were included, with a mean age and disease duration of 42.5¡11.8 years and
9.7¡5.3 years, respectively. The prevalence of squamous intraepithelial lesions was 6.8%. The prevalence of
human papillomavirus infection was 29%, with human papillomavirus subtype 59 being the most frequent.
Patients with human papillomavirus were younger than those without the infection (38.2¡11.2 vs. 44.2¡11.5
years, respectively; p=0.05), and patients with the virus had higher daily prednisone doses (12.8¡6.8 vs.
9.7¡6.7 mg, respectively; p=0.01) and cumulative glucocorticoid doses (14.2¡9.8 vs. 9.7¡7.3 g, respectively;
p=0.005) compared with patients without. Patients with human papillomavirus infection more frequently
received rituximab than those without (20.9% vs. 8.5%, respectively; p=0.03). In the multivariate analysis, only
the cumulative glucocorticoid dose was associated with human papillomavirus infection.
CONCLUSIONS: The cumulative glucocorticoid dose may increase the risk of human papillomavirus infection.
Although rituximab administration was more frequent in patients with human papillomavirus infection, no
association was found. Screening for human papillomavirus infection is recommended in women with systemic
lupus erythematosus.
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& INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystemic
disease that mainly affects young women and is caused by
autoantibodies to a variety of autoantigens. SLE has been
associated with cervical dysplasia (1-3), for which some risk
factors have also been identified, including a history of
sexually transmitted disease, early onset of sexual activity,
the number of sexual partners, and low educational levels
(3). Immunosuppressive therapy can increase the risk of
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viral infections, such as cervical human papillomavirus
(HPV) infection, which is strongly associated with cervical
dysplasia (4,5). Furthermore, a high risk of vulvar cancers
has been found in patients with SLE, and one important
factor is the possibility of altered clearance of viruses,
particularly HPV, which is linked to this malignancy and
cervical cancer (6). A recent analysis of a multicenter SLE
cohort demonstrated that the standardized incidence ratio
(SIR) for cervical cancer is consistent with increased risk
(SIR 1.65, 95% CI 1.09-2.41) (7).
There is also a relationship between immunosuppressive
therapy and cervical abnormalities (8). However, some
studies have found no association between cervical HPV
infection and immunosuppressive therapy (3,9). In recent
years, new, targeted therapies have been administered to
SLE patients, and there has been some evidence for the
efficacy and safety of B cell depletion by anti-CD20 therapy
with rituximab. Although there was a case report of
rituximab administration and JC papovavirus infection in
a patient with non-Hodgkin lymphoma (10), the effect of
this type of therapy on cervical HPV infection is unknown.
In Mexico, the prevalence of HPV in cervical samples is
estimated at 9.3% (11), and the prevalence of cervical cancer
in women in the general population (aged $35 years old)
ranges between 0.5% and 0.9% (12). Mexican patients with
SLE have an elevated risk of major organ involvement (13).
This type of patient usually requires immunosuppressive
drugs and even biologic therapy, which may increase the
risk of squamous intraepithelial lesions in patients with
cervical HPV infection. The prevalence of cervical HPV
infections in Mexican women with SLE was recently
evaluated (5).
The objective of this study was to identify the prevalence
and factors associated with cervical HPV infection in
women with SLE.
& MATERIALS AND METHODS
Patient selection and assessment
In this cross-sectional study, consecutive female patients
who presented at the Systemic Autoimmune Disease
Research Unit of General Regional Hospital No. 36,
Instituto Mexicano del Seguro Social, Puebla, Mexico, and
fulfilled the 1997 American College of Rheumatology
revised criteria for the classification of SLE (14) were
recruited. Patients were eligible for the study if they were
married or sexually active. Patients were excluded if they
were pregnant or had had a hysterectomy, cervical cancer,
or a previous diagnosis of papillomavirus infection. None of
the patients had been immunized against any HPV
subtypes. The local institutional ethics committee approved
the study, and written informed consent was obtained from
all participants. All women with abnormal Pap smears were
referred for gynecologic follow-up.
The study visit for each participant included a structured
interview detailing demographic information and medical
history, including sexual, gynecological, and obstetric
histories, and a gynecological examination, including the
collection of samples for a Pap test and HPV test. The
Systemic Lupus Erythematosus Disease Activity Index,
validated for the Mexican population (mexSLEDAI) (15),
and the Systemic Lupus International Collaborating
Clinics/American College of Rheumatology damage index
(SLICC/ACR DI) for SLE (16) were used to assess disease
activity and damage, respectively. The drug history was
determined by chart review. The daily prednisone dose at
the study visit and the cumulative glucocorticoid (GC) dose
were measured. The continuous use of immunosuppressive
therapy (azathioprine, leflunomide, methotrexate, myco-
phenolic acid, and cyclophosphamide) and rituximab in the
three years before study recruitment was recorded.
Rituximab administration (261 g) was added to immuno-
suppressive treatment (azathioprine, leflunomide, metho-
trexate or mycophenolic acid) in patients with refractory
disease.
The genitalia were clinically examined by a single
gynecologist, who examined the vulva, vagina, and cervix
of each woman. Pap smears were collected using conven-
tional techniques. Briefly, the cervix was visualized after
insertion of a speculum into the vagina with rotation using
gentle pressure. A Cytobrush was inserted two-thirds of the
way into the endocervical canal and external cervix and was
rotated 360 ;˚ the material obtained was fixed on a micro-
scope slide. A second Cytobrush was inserted into the
endocervical canal, and the material obtained was deposited
in a 15 ml tube containing 3 ml of phosphate-buffered saline
(PBS) (137mM NaCl, 1.8mM KH2PO4, 2.7mM KCl, 10mM
Na2HPO4).
All Pap smears were evaluated by a cytopathologist who
was blinded to the results of the gynecological examina-
tions. Cervical cytology results were classified according to
the 2001 Bethesda system as negative for intraepithelial
lesion or malignancy; epithelial cell abnormalities that
include atypical squamous cells; low-grade squamous
intraepithelial lesion (LGSIL); high-grade squamous intrae-
pithelial lesion (HGSIL); squamous cell carcinoma; atypical
glandular cells; endocervical adenocarcinoma in situ;
adenocarcinoma; or other (17).
Determination of HPV in cervical smears
All samples were labeled and stored at -20 C˚ until DNA
extraction. Cervical smears were shaken vigorously and
centrifuged for 10 min at 4000 rpm. The pellets were
resuspended in 1 ml PBS, and a 0.5 ml aliquot was used
for DNA extraction using the QIAamp DNA Mini (Qiagen,
Hilden, Germany) kit, according to the manufacturer’s
recommendations. Purified DNA was suspended in 100 ml
of water and stored at -20 C˚ until use. DNA integrity was
verified by 1% agarose gel electrophoresis.
HPV detection by PCR assay
HPV was detected using PGMY09/11 primers (18) which
allow for the detection of more than 30 HPV genotypes.
The final volume of the PCR reaction was 25 ml, including
10.5 ml of the DNA sample, 10 pmol of each PGMY09/11
primer, and the Taq PCR Master Mix kit (Promega,
Madison, WI, USA). Amplification was performed in a
thermal cycler (PTC 200, MJ Research, Watertown, MA,
USA) using 40 cycles of 95 C˚ for 1 min and 55 C˚ for 1 min to
allow for alignment and 72 C˚ for 1 min to allow for
elongation. These cycles were followed by a final extension
at 72 C˚ for 5 min. A fragment of the cyclophilin gene was
amplified as a control for the samples. The amplification
products were analyzed by 1.5% agarose gel electrophor-
esis. The gels were stained with ethidium bromide (1 mg/
ml), observed in an ultraviolet transilluminator, and
photographed using a digital camera Canon (Melville, NY,
USA) (18-20).
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Identification of viral genotypes
HPV DNA genotyping was performed with the Linear
Array (LA) HPV assay (Roche Diagnostic) in samples with a
positive HPV PCR test. The LA assay uses the PGMY09/
PGMY11 primer set, which amplifies a 450-bp fragment of
the L1 gene, and it can detect 37 HPV genotypes (6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 56, 57, 58, 59, 61,
62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, and
CP6108). On each strip, two different concentrations of b-
globin probes are present, which serve as internal controls
to assure adequate amplifiable DNA in each specimen.
Beta-globin negative samples were considered inadequate
and genotyping test was repeated. Genital HPV has
traditionally been classified into low-risk (LR) and high-
risk (HR) types. HR HVP types are associated with HGSIL
and cervical cancer. The HPV types classified in the HR
group include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68,
73, and 82 (21).
The assay was performed according to the manufacturer’s
instructions. Briefly, DNA was amplified in a total volume
of 100 ml, containing 50 ml of sample DNA and 50 ml of the
master mixture provided by the manufacturer. The ampli-
fication protocol was as follows: 9 min of denaturation at
95 C˚; 40 cycles of 30 s of denaturation at 95 C˚, 1 min of
annealing at 55 C˚, and 1 min of elongation at 72 C˚; and a
final extension for 5 min at 72 C˚. After amplification, the
whole PCR product was denatured and hybridized with
oligonucleotide probes immobilized on strips. After a
stringent wash, the hybrids were detected by the addition
of streptavidin-horseradish peroxidase conjugate, which
binds to the biotinylated PCR primers, and a substrate
(hydrogen peroxide and 3, 39, 5, 59-tetramethylbenzidine)
that generates a purple precipitate at the probe line.
Statistical analysis
Quantitative variables are expressed as means ¡ stan-
dard deviations (SDs), and qualitative variables are
expressed as frequencies (%). The means of two groups
were compared using Student’s unpaired t-test. Proportions
between groups were compared using the chi-square test or
Fisher’s exact test. Odds ratios (ORs) with 95% confidence
intervals (CIs) were used to estimate the association
between each possible risk factor and cervical HPV
infection.
Logistic regression was used to determine the indepen-
dent risk factors for cervical HPV infection, and variables
with a significance of p,0.05 in the univariate analysis
were included in the multivariate analyses. The final models
were assessed for interaction effects. All analyses were two-
tailed, and p-values #0.05 were considered significant. The
statistical analysis was performed using SPSS for Windows,
version 18.0 (SPSS, Chicago, IL, USA).
& RESULTS
The sociodemographic, clinical, and treatment variables
of the 148 SLE patients included are shown in Table 1. Sixty-
three patients (42.5%) were postmenopausal. At the study
visit, the mean mexSLEDAI and SLICC scores were 2.3¡2.1
and 1.3¡0.4, respectively. The meanmexSLEDAI score since
disease onset was 3.54¡1.96. Eighteen patients had received
rituximab, of whom three were non-responders (16.6%). The
median daily doses of each immunosuppressive agent were
azathioprine 100 mg per day, methotrexate 15 mg per week,
leflunomide 20 mg per day, and mycophenolic acid 2 g per
day. Most patients who had received intravenous cyclopho-
sphamide had been administered the NHI protocol.
Forty-three patients (29%) had HPV infections, of whom
31 (72%) had HR HPV infections, and 20 (13.5%) had $2
HPV infections. The most prevalent HR HVP types were 59
(34.8%), 18 (18.6%), 62 (16.2%), and 16 (13.9%).
Cervical HPV (+) patients were younger than cervical
HPV (-) patients (38.2¡11.2 years vs. 44.2¡11.5 years,
respectively; p= 0.05) and had higher prednisone doses
(12.8¡6.8 mg vs. 9.7¡6.7 mg, respectively; p= 0.01) and
higher cumulative GC doses (14.2¡9.8 g vs. 9.7¡7.3 g,
respectively; p= 0.005). The mexSLEDAI score and SLICC
score did not significantly differ between the two groups.
Although cervical HPV (+) patients were more likely to
have received immunosuppressive therapy than cervical
HPV (-) patients, the difference was not significant (58.1%
vs. 54.1%, respectively; p = 0.7). However, mycophenolic
acid therapy (9.3% vs. 0.9%, respectively, p = 0.02; OR: 10.6,
95% CI: 1.15-98.4) and prior rituximab therapy (20.9% vs.
8.5%, respectively, p = 0.03; OR: 2.8, 95% CI: 1.03-7.7) were
more frequent in cervical HPV (+) patients than in HPV (-)
patients. The cumulative cyclophosphamide dose was
higher in HPV (+) patients than in HPV (-) patients
(6.3¡3.4 g vs. 5.2¡3.0 g, respectively; p= 0.05). Table 2
shows the differences between patients with and without
cervical HPV infections. The prevalence of cervical HVP
infection did not differ significantly according to the
response to rituximab therapy.
In the logistic analysis, only the cumulative GC dose was
associated with cervical HPV infection (OR: 1.03; 95% CI
1.01-1.11), with no association found with other traditional
risk factors or immunosuppressive treatments. Similarly,
there was no association with rituximab therapy.
Table 1 - Sociodemographic, clinical, and treatment
characteristics of patients with systemic lupus
erythematosus.
Variable N=148
Age, mean ¡ SD, years 42.5¡11.8
Formal education, mean ¡ SD, years 11.0¡4.4
Current smoker, n (%) 16 (10.6)
Age at first intercourse, mean ¡ SD, years 20.4¡3.7
Pregnancies, n (%) 133 (88.1)
0 18 (12.1)
1-2 62 (41.8)
3 or more 68 (45.9)
Number of sexual partners, n (%)
1 105 (70.9)
2 24 (16.3)
3 or more 19 (12.8)
Oral contraceptive use, n (%) 1 (0.7)
Disease duration, mean ¡ SD, years 9.7¡5.3
Previous medication
Antimalarials, n (%) 144 (95.4)
Daily prednisone (mg/d), mean ¡ SD 10.5¡6.8
Cumulative GC dose (g), mean ¡ SD 11.0¡8.4
Azathioprine, n (%) 47 (31.3)
Methotrexate, n (%) 29 (19.2)
Leflunomide, n (%) 9 (5.9)
Mycophenolic acid, n (%) 5 (3.3)
Cyclophosphamide, n (%) 4 (2.7)
Cumulative cyclophosphamide (g), mean ¡ SD 5.8¡3.2
Rituximab, n (%) 18 (12.1)
SD: Standard deviation; GC: glucocorticoid.
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Six percent of patients had low-grade squamous intrae-
pithelial lesions, and 0.6% had high-grade squamous
intraepithelial lesions, according to the 2001 Bethesda
system classification. None of the patients had squamous
cell carcinoma or adenocarcinoma.
& DISCUSSION
Several studies have investigated the prevalence of and
risk factors for cervical HPV infection in SLE patients.
Although immunosuppressive therapy has been studied as
a risk factor for HPV infection in these patients with
contradictory results (3-5,8), biologic therapy has not
previously been analyzed as a possible risk factor.
We found a prevalence of cervical HVP infection of 29%,
which was higher than in some studies. Tam et al. (22)
found that 12.5% of SLE patients had a persistently high risk
of HPV, which increased to 25% three years after diagnosis.
Rojo-Contreras et al. (5) recently found a prevalence of
14.7% in Mexican SLE patients. In contrast, a Brazilian study
found a prevalence of 80.7% (9). These differences may be
due to environmental, cultural, or genetic risk factors or
geographical variations (23). Our study assessed a greater
number of HPV types than previous studies (24). HR HPV
type 59 was the most prevalent type in our cohort (34.8%).
Tam et al. (3) found subtype 59 in only 1.2% of patients with
SLE, in whom the most prevalent HR HPV subtype was 16
(4.7%). In addition, 13.5% of our patients had $2 HPV
subtypes, which is higher than in some studies (3,5) but
lower than the 21.7% found by Klumb et al. (24).
The prevalence of cervical HPV infection decreases
sharply in women after the age of 30 years (25). We found
a higher prevalence of cervical HPV in younger patients
with SLE, possibly related to sexual activity. However, we
found no associations between the variables measuring
sexual activity and infection, possibly due to the cross-
sectional nature of the study.
Disease activity may be associated with abnormal cervical
cytology in juvenile-onset SLE (26). However, we found no
association between cervical HPV infection and lupus
activity measured by the mexSLEDAI at the study visit or
the mean activity since disease onset.
The cumulative GC dose was the only risk factor
associated with cervical HPV infection in our SLE patients.
The cumulative GC dose was recently associated with Toll-
like-receptor (TLR) downregulation and the risk of HPV
infection (27). Prednisolone suppressed the functions of
TLR-stimulated human plasmacytoid dendritic cells,
thereby reducing the ability to clear HPV infection (28).
The recent addition of biologic therapies, such as
rituximab, to the treatment of SLE led us to include this
factor in our analysis to identify any possible association
with the risk of cervical HVP infection. The possible
mechanism by which anti-CD20 therapy might increase
susceptibility to HPV infection is unclear. Rituximab
administration results in profound depletion of normal B
cells for several months, but immunoglobulin levels remain
unaltered in most patients. These effects may occur because
long-lived plasma cells do not express CD20. The lack of an
effect on immunoglobulin levels suggests that rituximab
administration could have a minimal effect on the occur-
rence of infections. Depletion of B cells would be expected to
result in poor antibody responses to new antigens. Several
studies have reported that patients receiving rituximab
exhibit decreased to absent humoral responses to new
Table 2 - Sociodemographic, clinical, and treatment characteristics of patients with systemic lupus erythematosus with
and without cervical HPV infection.*
Variable Patients with HPV (N=43) Patients without HPV (N=105) p-value
Age, mean ¡ SD, years 38.2¡11.2 44.2¡11.5 0.05
Current smoker, n (%) 4 (9.3) 12 (11.4) 0.40
Formal education, mean ¡ SD, years 10.7¡4 11.2¡4.6 0.30
Pregnancies, n (%)
0 8 (18.6) 10 (9.5) 0.07
1-2 21 (48.8) 43 (41) 0.08
3 or more 14 (32.6) 52 (49.5) 0.06
Age at first intercourse, mean ¡ SD, years 20.4¡3.4 20.5¡3.8 0.80
Number of sexual partners, n (%)
1 27 (62.7) 78 (74.2) 0.30
2 8 (18.6) 16 (15.2) 0.40
3 or more 8 (18.6) 11 (10.4) 0.20
Oral contraceptive use, n (%) 1 (2.3) 0 (0) 0.29
Disease duration, mean ¡ SD years 9.5¡6.2 9.8¡6.1 0.77
mexSLEDAI at study visit, mean ¡ SD, score 2.3¡2.1 2.1¡2.0 0.70
mexSLEAI since diagnosis, mean ¡ SD, score 4.0¡2.0 3.3¡1.9 0.08
SLICC/ACR DI, mean ¡ SD, score 1.2¡0.5 1.3¡0.4 0.80
Previous medication
Antimalarials, n (%) 36 (83.7) 81 (77.1) 0.50
Daily prednisone dose, mean ¡ SD, mg 12.8¡6.8 9.7¡6.7 0.01
Cumulative GC dose, mean ¡ SD, mg 14.2¡9.8 9.7¡7.3 0.005
Azathioprine, n (%) 16 (37.2) 30 (28.5) 0.33
Methotrexate, n (%) 5 (11.6) 25 (23.8) 0.17
Leflunomide, n (%) 5 (11.6) 6 (4.7) 0.28
Mycophenolic acid, n (%) 4 (9.3) 1 (0.9) 0.02
Cyclophosphamide, n (%) 3 (6.9) 1 (0.9) 0.07
Cumulative CYC (g), mean ¡ SD 6.3¡3.4 5.2¡3.0 0.50
Rituximab, n (%) 9 (20.9) 9 (8.5) 0.03
*HPV: human papillomavirus; SD: standard deviation; GC: glucocorticoid; CYC: cyclophosphamide.
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antigens compared with recall antigens (29-31). Our results
showed that patients treated with rituximab had a higher
prevalence of cervical HPV infection than those treated with
conventional immunosuppressive therapy. However, this
possible association was lost after adjusting for others
factors, such as GC. Similarly, Abud-Mendoza et al. (32)
found no associations between HPV infection and rituximab
in patients with SLE and rheumatoid arthritis. One possible
reason why rituximab was not associated with cervical HPV
infection might have been that other routes, such as the
innate immune response, could have been affected in these
patients. Innate immune abnormalities have been reported
in patients with SLE and HPV (27).
In the univariate analysis, mycophenolic acid was
associated with cervical HPV infection, although the
association disappeared in the multivariate analysis, possi-
bly because few patients were analyzed. A very recent
Mexican study detected low levels of B and NK cells and an
enhanced risk of HPV infection in SLE patients receiving
mycophenolate mofetil (32). We also found no association
between HPV infection and other immunosuppressive
therapies, such as azathioprine and methotrexate. Rojo-
Contreras et al. (5), who also studied Mexican SLE patients,
found no association between cervical HPV and azathiopr-
ine but did find an association with methotrexate and a
longer duration of prednisone therapy (5). These differences
may be explained by the different methods used to assess
the impact of these therapies and to geographical variations
in the prevalence of HPV in Mexican women (23). A positive
association has been found between cervical dysplasia and
cyclophosphamide (33,34), and Klumb et al. (24) found
higher cumulative cyclophosphamide doses in SLE patients
with HPV infections. In our study, cyclophosphamide was
not associated with cervical HPV infection.
The importance of vaccination, including HPV immuni-
zation, in preventing and reducing infectious morbidity and
mortality in SLE patients was recently suggested (35,36).
However, the onset of some autoimmune diseases, particu-
larly SLE, following HPV vaccination has also been reported
(37). Mok et al. (38) evaluated the immunogenicity and
safety of GARDASIL, a quadrivalent HPV vaccine, in
patients with SLE, and they found that the vaccine was
well tolerated and reasonably effective in patients with
stable SLE and that it did not induce an increase in lupus
activity or flares.
Our study is not without limitations. First, there were the
inherent difficulties of cross-sectional studies and the effect
of sample size in establishing causal relationships and
identifying incidence. Longitudinal studies with more
patients who have received biologic therapy are necessary
to establish associations. All the patients receiving rituximab
had been refractory to conventional treatment, which was
still continued during rituximab therapy, and the combina-
tion of therapies could have resulted in a greater risk of
HPV infection than the administration of biologic therapy
alone. Furthermore, although we measured the cumulative
GC and cyclophosphamide doses, we did not measure the
cumulative doses of other immunosuppressive agents,
identifying only those drugs that had been administered
and the median daily doses. In addition, we did not
measure B cell counts to reflect depletion due to rituximab
treatment or the role of other elements of the innate immune
system.
In conclusion, women with SLE, and particularly younger
patients, had an increased prevalence of cervical HPV
infection. Our results suggest that the cumulative GC dose
may increase the risk of HPV. Although rituximab admin-
istration was more frequent in patients with HPV infections,
no associations were found. Screening for HPV infection is
recommended in women with SLE, particularly those
receiving high GC doses. Longitudinal studies are necessary
to demonstrate these possible associations and to evaluate
the natural history of cervical HPV infection in women with
SLE who are receiving biologic therapies.
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